Home
HelpTest ID VIP Vasoactive Intestinal Polypeptide (VIP), Plasma
Useful For
Detection of vasoactive intestinal polypeptide producing tumors in patients with chronic diarrheal diseases
Method Name
Radioimmunoassay (RIA)
Reporting Name
Vasoactive Intestinal Polypeptide,PSpecimen Type
Plasma EDTACollection Container/Tube: Lavender top (EDTA)
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Collection Instructions:
1. Fasting (8 hours)
2. Spin down and immediately freeze.
Additional Information: This test should not be requested on patients who have recently received radioactive material.
Forms: If not ordering electronically, complete, print, and send an Oncology Test Request Form (T729) with the specimen
(http://www.mayomedicallaboratories.com/it-mmfiles/oncology-request-form.pdf)
Specimen Minimum Volume
0.55 mL
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| Plasma EDTA | Frozen | 90 days |
Clinical Information
Vasoactive intestinal polypeptide (VIP) was originally isolated from porcine small intestine and was recognized by its potent vasodilator activity. This brain/gut hormone has widespread distribution and is present in neuronal cell bodies localized in the central nervous system, digestive, respiratory, and urogenital tracts, exocrine glands, and thyroid and adrenal glands. VIP has a wide scope of biological actions. The main effects of VIP include relaxation of smooth muscle (bronchial and vascular dilation), stimulation of gastrointestinal water and electrolyte secretion, and release of pancreatic hormones.
VIP-producing tumors (VIPomas) are rare; most (90%) are located in the pancreas. Watery diarrhea, hypokalemia, and achlorhydria are key symptoms.
Reference Values
<75 pg/mL
Cautions
This test should not be requested in patients who have recently received radioisotopes, therapeutically or diagnostically, because of potential assay interference. A recommended time period before collection cannot be made because it will depend on the isotope administered, the dose given and the clearance rate in the individual patient. Specimens will be screened for radioactivity prior to analysis. Radioactive samples received in the laboratory will be held and assayed after the radioactivity has sufficiently decayed. This will result in a test delay.
Day(s) Performed
Monday, Wednesday; 2 p.m.
Report Available
3 daysPerforming Laboratory
Mayo Medical Laboratories in Rochester
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.CPT Code Information
84586